{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:04:20Z","timestamp":1790060660608,"version":"4.0.1"},"reference-count":38,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T00:00:00Z","timestamp":1539561600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Addiction"],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and Aims<\/jats:title><jats:p>Expanding access to medication\u2010assisted treatment with buprenorphine is a cornerstone of the opioid crisis response, yet buprenorphine remains underutilized. Research has identified multiple barriers to prescribing buprenorphine. This study aimed to examine clinician characteristics, prescribing practices and barriers and incentives to prescribing buprenorphine among clinicians with a federal Drug Addiction Treatment Act of 2000 (DATA) waiver to prescribe buprenorphine for opioid use disorder treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Electronic survey of 4225 clinicians conducted between March and April 2018.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>United States.<\/jats:p><\/jats:sec><jats:sec><jats:title>Participants<\/jats:title><jats:p>Clinicians obtaining an initial federal DATA waiver or an increase in authorized patient limit to prescribe buprenorphine for opioid use disorder treatment in 2017.<\/jats:p><\/jats:sec><jats:sec><jats:title>Measurements<\/jats:title><jats:p>Descriptive statistics and multivariable logistic regression examined clinician characteristics, prescribing practices and primary barriers and incentives to prescribing buprenorphine or prescribing at or near the authorized patient limit.<\/jats:p><\/jats:sec><jats:sec><jats:title>Findings<\/jats:title><jats:p>Among respondents, 75.5% had prescribed buprenorphine since obtaining a DATA waiver; the mean (standard deviation) number of patients treated in the past month was 26.6 (40.3), and 13.1% of providers were prescribing at or near their patient limit in the past month. Lack of patient demand, cited by 19.4% of clinicians, was the most common primary barrier to prescribing buprenorphine or prescribing to the authorized patient limit, followed by time constraints in practice (14.6%) and insurance reimbursement, prior authorization or other insurance requirements (13.2%). Increased patient demand (22.2%), institutional support for buprenorphine treatment (12.5%) and increased reimbursement (12.2%) were the most endorsed primary incentives for buprenorphine prescribing. Multivariable logistic regression models identified multiple clinician characteristics associated with buprenorphine prescribing and prescribing at or near the authorized patient limit.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>US clinicians recently waivered to prescribe buprenorphine for opioid use disorder treatment appear to prescribe well below their patient limit, and many do not prescribe at all.<\/jats:p><\/jats:sec>","DOI":"10.1111\/add.14436","type":"journal-article","created":{"date-parts":[[2018,9,8]],"date-time":"2018-09-08T15:38:46Z","timestamp":1536421126000},"page":"471-482","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":126,"title":["Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder"],"prefix":"10.1111","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8598-2100","authenticated-orcid":false,"given":"Christopher M.","family":"Jones","sequence":"first","affiliation":[{"name":"Substance Abuse and Mental Health Services Administration  Rockville MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elinore F.","family":"McCance\u2010Katz","sequence":"additional","affiliation":[{"name":"Substance Abuse and Mental Health Services Administration  Rockville MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,10,15]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.2844"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6709e1"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2017\u20103520"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2017.304132"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2015.1424"},{"key":"e_1_2_6_7_1","unstructured":"US Department of Health and Human Services (USDHHS) Office of the Assistant Secretary for Planning and Evaluation.ASPE Research Brief: substance use the opioid epidemic and the child welfare system: key findings from a mixed methods study. Washington DC: USDHHS;2018."},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-012-2225-z"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2008.802"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.370"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002209.pub2"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002207.pub4"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505409"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.5416"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60358-9"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2012.301049"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2015.302664"},{"key":"e_1_2_6_18_1","unstructured":"Drug Addiction Treatment Act of 2000 Pub. L. No. 106\u2010310 114 Stat 1101."},{"key":"e_1_2_6_19_1","first-page":"44711","article-title":"Medication assisted treatment for opioid use disorders","volume":"81","author":"Substance Abuse and Mental Health Services Administration","year":"2016","journal-title":"Final Rule Fed Regist"},{"key":"e_1_2_6_20_1","unstructured":"Comprehensive Addiction and Recovery Act of 2016 Public Law no. 114\u2013198."},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-008-0686-x"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1300\/J069v25n04_09"},{"key":"e_1_2_6_23_1","first-page":"336","article-title":"Attending physicians\u2019 and residents\u2019 attitudes and beliefs about prescribing buprenorphine at an urban teaching hospital","volume":"38","author":"Cunningham C. O.","year":"2006","journal-title":"Fam Med"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1370\/afm.1595"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2008.06.006"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2017.10.002"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2010.05.004"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2018.01.015"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2016.10.005"},{"key":"e_1_2_6_30_1","unstructured":"American Society of Addiction Medicine (ASAM).ASAM National Practice Guideline for the Use of Medications in the Treatment of Addiction involving Opioid Use. Chevy Chase MD: ASAM;2015."},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-010-1377-y"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.12454"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2015.1129388"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000310"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2015.06.010"},{"key":"e_1_2_6_36_1","unstructured":"Rhode Island Department of Behavioral Healthcare Developmental Disabilities and Hospitals.Certification standards for Centers of Excellence June2016. Available at:http:\/\/www.bhddh.ri.gov\/quick_links\/pdf\/COE%20cert.%20standards_Final.pdf(accessed 23\u00a0May 2018) (Archived athttp:\/\/www.webcitation.org\/72hzLAgtA)."},{"key":"e_1_2_6_37_1","unstructured":"Substance Abuse and Mental Health Services Administration.Results from the 2016 National Survey on Drug Use and Health. Available at:https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/NSDUH\u2010DetTabs\u20102016\/NSDUH\u2010DetTabs\u20102016.htm(accessed 13\u00a0May 2018) (Archived athttp:\/\/www.webcitation.org\/72hzQSHGo)."},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.3474"},{"key":"e_1_2_6_39_1","first-page":"38","article-title":"Emergency department naloxone distribution: a Rhode Island department of health, recovery community, and emergency department partnership to reduce opioid overdose deaths","volume":"97","author":"Samuels E.","year":"2014","journal-title":"RI Med J"}],"container-title":["Addiction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fadd.14436","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/add.14436","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T11:47:05Z","timestamp":1694692025000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/add.14436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,15]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["10.1111\/add.14436"],"URL":"https:\/\/doi.org\/10.1111\/add.14436","archive":["Portico"],"relation":{},"ISSN":["0965-2140","1360-0443"],"issn-type":[{"value":"0965-2140","type":"print"},{"value":"1360-0443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,15]]},"assertion":[{"value":"2018-05-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-31","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}